References
[1] Office of National Statistics. (2016). https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregisteredinenglandandwalesseriesdr/20152.
[2] Mahoney, R., Regan, C., Katona, C., and Livingston, G. (2005). Anxiety and depression in family caregivers of people with Alzheimer disease: the LASER-AD study. Am J Geriatr Psychiatry, 13:795-801.
[3] Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, G. C., Huntley, J., Ames, D., et al. (2017). Dementia prevention, inter-vention, and care. www.thelancet.com. Published online July 20, 2017.
[4] Erickson, K. I., Prakash, R. S., Voss, M. W., Chaddock, L., Hu, L., Morris, K. S., et al. (2009). Aerobic Fitness is Associated with Hippocampal Volume in Elderly Humans. Hippocampus, 19(10): 1030-1039.
[5] Mehra, R. D., Sharma, K., Nyakas, C., Vij, U. (2005). Estrogen receptor α and β immunoreactive neurons in normal adult and aged female rat hippocampus: a qualitative and quantitative study. Brain Res., 1056: 22-35.
[6] Wnuk, A., Korol, D. L., Erickson, K. I. (2012). Estrogens, hormone therapy, and hippocampal volume in postmenopausal women. Maturitas, 73: 186-190.
[7] Braak, H., Braak, E. (1990). Neuropathological staging of Alzheimer-related changes. Acta Neuropathol., 182: 239-259.
[8] Csernansky, J. G., Wang, L., Swank, J. J. G., Miller, J. P., Gado, M., McKeel, D., et al. (2005). Preclinical detection of Alz-heimer’s disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage, 25: 783-792.
[9] Hackert, V. H., den Heijer, T., Oudkerk, M., Koudstaal, M., Hofman, A., Breteler, M. M. B. (2002). Hippocampal head size associated with verbal memory performance in nondemented elderly. Neuroimage, 17: 1365-1372.
[10] O’Driscoll, G. A., Florencio, P. S., Gagnon, D., Wolff, D., Anne-Lise, V., Benkelfat, C. M., et al. (2001). Amyg-dala-hippocampal volume and verbal memory in first-degree relatives of schizophrenic patients. Psychiatry Res., 107: 75-85.
[11] Pike, C. J., Carroll, J. C., Rosario, E. R., Barron, A. (2009). Protective actions of sex steroid hormones in Alzheimer’s disease. Front Neuroendocrinology, 30(2): 239-258.
[12] Bean, L. A., Lanov, L., Foster, T. C. M. (2014). Estrogen Receptors, the Hippocampus, and Memory. Neuroscientist, 20(5): 534-545.
[13] Eberling, J. L., Wu, C., Haan, M. N., Mungas, D., Buonocore, M., Jagust, W. J. (2003). Preliminary evidence that estrogen protects against age-related hippocampal atrophy. Neurobiol Aging, 24(5): 725-32.
[14] Epperson, C. N., Sammel, M. D., Freeman, E. W. (2013). Menopause Effects on Verbal Memory: Findings From a Longitudinal Community Cohort. J Clinical Endocrinol Metab., 98(9): 3829-3838.
[15] Braak, H., Braak, E. (1990). Alzheimer’s disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol., 49: 215-224.
[16] Goodman, Y., Bruce, A. J., Cheng, B., Mattson, M. B. (1996). Estrogens Attenuate and Corticosterone Exacerbates Excitotox-icity, Oxidative Injury, and Amyloid β-Peptide Toxicity in Hippocampal Neurons. J of Neurochemistry, 66: 1836-1844.
[17] Gouldm E,, Woolley, S. W., Frankfurt, M., McEwen, B. S. (1990). Gonadal Steroids Regulate Dendritic Spine Density in Hip-pocampal Pyramidal Cells in Adulthood. J of Neuroscience, 10(4): 1286-91.
[18] Packard, M. G., Teather, L. A. (1997). Intra-hippocampal estradiol infusion enhances memory in ovariectomized rats. Neuroreport, 29: 8(14): 3009-13.
[19] Barouk, S., Hintz, T., Ping, L., MacLusky, N. J., Scharfman, H. E. (2011). 17β-Estradiol Increases Astrocytic Vascular Endo-thelial Growth Factor (VEGF) in Adult Female Rat Hippocampus. Endocrinology, 152(5): 1745-1751.
[20] Frankish, H., Horton, R. (2017). Prevention and management of dementia: a priority for public health. The Lancet, July 20, 2017. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31756-7/fulltext.
[21] Shao, H., Breitner, J. C. S., Whitmer, R. A.,Wang, J., Hayden, K., Wengreen, H., et al. (2012). For the Cache County Investi-gators. Hormone therapy and Alzheimer disease dementia. New findings from the Cache County Study. Neurology, 79(18): 1846-1852.
[22] Kawas, S., Resnick, A., Morrison, R., Brookmeyer, M., Corrada, A., Zonderman, C., et al. (1997). A prospective study of es-trogen replacement therapy and the risk of developing Alzheimer’s disease. The Baltimore Longitudinal Study of Aging, https://doi.org/10.1212/WNL.48.6.1517.
[23] Whitmer, R. A., Quesenberry, Jr C. P., Zhou, J., Yaffe, K. (2011). Timing of hormone therapy and dementia: the critical window theory revisited. Annals Neurology, 69(1): 163-169.
[24] Craig, C. M., Maki, P. M., Murphy, D. G. M. (2005). The Women’s Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol., 4: 190-194.
[25] Wang, P. N., Liao, S. Q., Liu, R. S., Liu, C. Y., Chao, H. T., Lu, S. R., et al. (2000). Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology, 54(11): 2061-6.
[26] Mulnard, R. A., Cotman, C. W., Kawas, C., van Dyck, C. H., Sano, M., Doody, R., et al. (2000). Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. JAMA, 283(8): 1007-15.
[27] Henderson, V. W., Paganini-Hill, A., Miller, B. L., Elble, P. F., Reyes, D., Shoupe, C. A., et al. (2000). Estrogen for Alzheimer’s disease in women: randomized, double-blind, placebo-controlled trial. Neurology, 54(2): 295-301.
[28] Pintzka, C. W. S. and Håberg, A. K. (015). Perimenopausal hormone therapy is associated with regional sparing of the CA1 subfield: a HUNT MRI study. Neurobiology of Aging, 36: 2555-2562.
[29] Hill, A. B. (1965). The environment and disease: association or causation? Proc Royal Soc Med., 58: 295-300.
[30] Maki, P. M. (2013). The Critical Window Hypothesis of Hormone Therapy and Cognition: A Scientific Update on Clinical Studies. Menopause, 20(6): 695-709.
[31] Henderson, V. W., Benke, K. S., Green, R. C., Cupples, L. A., Farrer, L. A. (2005). Postmenopausal hormone therapy and Alzheimer’s disease risk: interaction with age. J Neurol Neurosurg Psychiatry, 76(1): 103-5.
[32] Lord, C., Buss, C., Lupien, S. J., Pruessner, J. C. (2008). Hippocampal volumes are larger in postmenopausal women using estrogen therapy compared to past users, never users and men: A possible window of opportunity effect. Neurobiology of Aging, 29(1): 95-101.
[33] Majumdar, S. R., Almasi, E. A., Stafford, R. S. (2004). Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA, 292(16): 1983-1988.
[34] Anderson, G. L., Chlebowski, R. T., Aragaki, A. K., Kuller, L. H., Manson, J. E., Margery, G., et al. (2012). Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. The Lancet, 13: 476-86.
[35] Zhang, S. M., Manson, J. E., Rexrode, K. M., Cook, N. R., Buring, J. E., Lee, I. M. (2007). Use of oral conjugated estrogen alone and risk of breast cancer. Am J Epidemiol., 165(5): 524-9.
[36] Tabori, N. E., Stewart, L. S., Znamensky, V., Romeo, R. D., Alves, R. E., McEwen, B. S., et al. (2005). Ultrastructural evidence that androgen receptors are located at extranuclear sites in the rat hippocampal formation. Neuroscience, 130: 151-163.
[37] Pike, C. J. (2001). Testosterone attenuates b-amyloid toxicity in cultured hippocampal neurons. Brain Research, 919: 160-165.
[38] Lv, W., Du, N., Liu, Y., Fan, X., Wang, Y., Jia, X., et al. (2016). Low Testosterone Level and Risk of Alzheimer’s Disease in the Elderly Men: A Systematic Review and Meta-Analysis. Mol Neurobiol., 53(4): 2679-84.
[39] Public Health England. (2018). Prevention must be the heart of the NHS long-term plan. September 6. https://www.gov.uk/government/news/prevention-must-be-the-heart-of-the-nhs-long-term-plan.